Over Half Of Americans Say ‘Big, Beautiful Bill’ Going To Raise Health Care Costs: Poll

More than half of Americans — 57 percent — said in a new survey that they think the GOP’s sweeping package extending tax cuts and slashing welfare services will increase their health-care costs.

Thirteen percent in the CBS/YouGov poll released Sunday said that the “big, beautiful bill” will lower their health-care costs and 33 percent said there will be no impact.

While the Congressional Budget Office has not yet released a final estimate for the measure as enacted, it projected that 16 million people would lose their health insurance by 2034 under an earlier House-passed version of the bill. This analysis has been the basis for many Democrats’ messaging around health care, and health-care advocates have still warned that the final version could be devastating to communities relying on Medicaid.

The sprawling package permanently extends many of the temporary tax cuts passed by Republicans during President Trump’s first term, alongside making deep spending reductions to Medicaid, the Supplemental Nutrition Assistance Program (SNAP), and other welfare programs. The measure would primarily benefit wealthy Americans, an analysis by the Yale Budget Lab found last month.

Democrats have assailed the legislation as a historic transfer of wealth from the poor to the rich and are looking to message around its cuts to health care for the 2026 midterms — even if some of the package’s most significant changes don’t kick in until 2028.

Overall, six in 10 questioned in the CBS/YouGov survey disapprove of the GOP megabill. A similar percentage said that it will help wealthy people and hurt poor people. A separate AP-NORC poll released Saturday found that nearly two-thirds of Americans think the legislation will do more to help wealthy people.

In the CBS/YouGov poll, 40 percent of respondents said they thought the measure will increase their taxes. Another 32 percent said they thought their taxes will not be impacted either way.

A majority — 56 percent — said that they tied issues regarding the megabill significantly to how they evaluate President Trump’s second term. A plurality of Americans, 44 percent, said they had a “general sense” of the content of the legislation alongside some specifics. Meanwhile, roughly two in 10 — 22 percent — said they had a general idea of it but lacked specifics.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square